Johnson & Johnson (JNJ) Shares Bought by Westbourne Investment Advisors Inc.

Westbourne Investment Advisors Inc. boosted its stake in Johnson & Johnson (NYSE:JNJ) by 0.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,820 shares of the company’s stock after buying an additional 70 shares during the period. Johnson & Johnson accounts for 1.8% of Westbourne Investment Advisors Inc.’s portfolio, making the stock its 17th largest position. Westbourne Investment Advisors Inc.’s holdings in Johnson & Johnson were worth $2,225,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Regent Investment Management LLC boosted its stake in Johnson & Johnson by 2.9% in the second quarter. Regent Investment Management LLC now owns 46,617 shares of the company’s stock worth $6,167,000 after buying an additional 1,297 shares during the period. Pecaut & CO. boosted its stake in Johnson & Johnson by 16.1% in the second quarter. Pecaut & CO. now owns 30,581 shares of the company’s stock worth $4,046,000 after buying an additional 4,250 shares during the period. Vaughan Nelson Investment Management L.P. boosted its stake in Johnson & Johnson by 0.8% in the second quarter. Vaughan Nelson Investment Management L.P. now owns 235,650 shares of the company’s stock worth $31,174,000 after buying an additional 1,875 shares during the period. Winslow Evans & Crocker Inc. boosted its stake in Johnson & Johnson by 1.8% in the second quarter. Winslow Evans & Crocker Inc. now owns 18,644 shares of the company’s stock worth $2,464,000 after buying an additional 328 shares during the period. Finally, Cascade Investment Advisors Inc. boosted its stake in Johnson & Johnson by 0.3% in the second quarter. Cascade Investment Advisors Inc. now owns 7,048 shares of the company’s stock worth $932,000 after buying an additional 23 shares during the period. 66.06% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson (NYSE JNJ) traded up 0.01% during midday trading on Friday, hitting $133.10. The stock had a trading volume of 4,270,571 shares. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $137.08. The stock has a market capitalization of $357.24 billion, a PE ratio of 22.52 and a beta of 0.78. The stock’s 50-day moving average is $133.09 and its 200-day moving average is $126.30.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.79 by $0.04. The business had revenue of $18.84 billion during the quarter, compared to analysts’ expectations of $18.94 billion. Johnson & Johnson had a return on equity of 26.76% and a net margin of 22.52%. The firm’s quarterly revenue was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.74 earnings per share. On average, equities research analysts anticipate that Johnson & Johnson will post $7.18 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 2.52%. The ex-dividend date is Friday, August 25th. Johnson & Johnson’s payout ratio is 56.76%.

ILLEGAL ACTIVITY NOTICE: “Johnson & Johnson (JNJ) Shares Bought by Westbourne Investment Advisors Inc.” was first posted by BNB Daily and is the sole property of of BNB Daily. If you are reading this story on another site, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be read at https://www.baseball-news-blog.com/2017/08/13/westbourne-investment-advisors-inc-has-2-23-million-position-in-johnson-johnson-jnj-updated-updated-updated.html.

A number of analysts have recently weighed in on JNJ shares. Barclays PLC reaffirmed an “equal weight” rating and set a $130.00 target price (up previously from $125.00) on shares of Johnson & Johnson in a research report on Monday, April 17th. BTIG Research reissued a “hold” rating on shares of Johnson & Johnson in a report on Wednesday, April 19th. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $128.54 price target on the stock in a report on Monday, April 24th. Jefferies Group LLC reissued a “hold” rating and issued a $135.00 price target (down previously from $140.00) on shares of Johnson & Johnson in a report on Sunday, May 14th. Finally, J P Morgan Chase & Co raised shares of Johnson & Johnson from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $123.64 to $140.00 in a report on Monday, May 15th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. Johnson & Johnson currently has a consensus rating of “Hold” and an average price target of $133.72.

In other Johnson & Johnson news, VP Paulus Stoffels sold 102,692 shares of Johnson & Johnson stock in a transaction on Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the sale, the vice president now owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Dominic J. Caruso sold 82,591 shares of Johnson & Johnson stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $136.72, for a total value of $11,291,841.52. Following the completion of the sale, the vice president now directly owns 226,693 shares of the company’s stock, valued at approximately $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is currently owned by insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply